CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Leuk Res. 2024 Apr:139:107479. doi: 10.1016/j.leukres.2024.107479. Epub 2024 Mar 11.

Authors

Xiaoyi Hu¹, Asiri Ediriwickrema¹, Atif Saleem², Brent Tan², Naveen Pemmaraju³, Gabriel N Mannis⁴

Affiliations

¹ Department of Medicine, Division of Hematology, Cancer Institute, Stanford University, Stanford, CA, USA.
² Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Medicine, Division of Hematology, Cancer Institute, Stanford University, Stanford, CA, USA. Electronic address: gmannis@stanford.edu.

PMID: 38492495
DOI: 10.1016/j.leukres.2024.107479

No abstract available

Keywords: BPDCN; CD123; Daratumumab; Tagraxofusp; Venetoclax.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal*
Bridged Bicyclo Compounds, Heterocyclic*
Dendritic Cells
Hematologic Neoplasms* / therapy
Humans
Interleukin-3 Receptor alpha Subunit
Neoplasms*
Proto-Oncogene Proteins c-bcl-2 / genetics
Proto-Oncogene Proteins c-bcl-2 / metabolism
Recombinant Fusion Proteins*
Skin Neoplasms*
Sulfonamides*

Substances

daratumumab
Interleukin-3 Receptor alpha Subunit
venetoclax
tagraxofusp
Proto-Oncogene Proteins c-bcl-2
BCL2 protein, human
Antibodies, Monoclonal
Recombinant Fusion Proteins
Sulfonamides
Bridged Bicyclo Compounds, Heterocyclic